NCT03244800 - A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 4, 2017

Primary Completion Date

January 23, 2018

Study Completion Date

January 23, 2018

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

MEDI0382

MEDI0382 will be administered subcutaneously once daily for 49 days.

DRUG

Placebo

Placebo will be administered subcutaneously once daily for 49 days.

Trial Locations (5)

Research Site, Berlin

Research Site, Magdeburg

Research Site, Neuss

Research Site, Mainz

Research Site, Neu-Ulm